$1.67 Billion is the total value of Avoro Capital Advisors LLC's 35 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 53.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | IMMUNOMEDICS INC | $252,785,000 | -31.5% | 17,714,461 | 0.0% | 15.11% | -10.8% | |
| MRTX | MIRATI THERAPEUTICS INC | $203,535,000 | -9.9% | 4,798,101 | 0.0% | 12.17% | +17.2% | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $139,141,000 | -8.7% | 1,275,000 | +35.1% | 8.32% | +18.9% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $124,047,000 | -10.8% | 1,980,000 | +0.8% | 7.42% | +16.1% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $115,804,000 | -12.7% | 1,360,000 | -0.6% | 6.92% | +13.6% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $96,998,000 | -14.0% | 10,125,000 | +8.5% | 5.80% | +11.9% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $90,810,000 | -6.8% | 10,261,039 | +18.5% | 5.43% | +21.3% |
| HZNP | Sell | HORIZON PHARMA PLC | $84,999,000 | -2.7% | 4,350,000 | -2.5% | 5.08% | +26.7% |
| ARGX | Buy | ARGENX SEsponsored adr | $82,620,000 | +44.2% | 860,000 | +13.8% | 4.94% | +87.7% |
| AMRN | Buy | AMARIN CORP PLCsponsored adr | $75,876,000 | +15.3% | 5,575,000 | +37.8% | 4.54% | +50.1% |
| ZGNX | Buy | ZOGENIX INC | $72,009,000 | -0.4% | 1,975,000 | +35.5% | 4.30% | +29.6% |
| LOXO | New | LOXO ONCOLOGY INC | $45,523,000 | – | 325,000 | +100.0% | 2.72% | – |
| TCDA | Sell | TRICIDA INC | $41,265,000 | -23.8% | 1,750,000 | -1.2% | 2.47% | -0.7% |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $27,753,000 | – | 1,128,584 | +100.0% | 1.66% | – |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $25,362,000 | -74.4% | 225,000 | -51.4% | 1.52% | -66.7% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $22,620,000 | -41.9% | 1,000,000 | -4.6% | 1.35% | -24.4% |
| TGTX | Buy | TG THERAPEUTICS INC | $19,475,000 | -17.2% | 4,750,000 | +13.1% | 1.16% | +7.8% |
| Sell | INTEC PHARMA LTD | $18,850,000 | +29.8% | 2,500,000 | -2.8% | 1.13% | +69.0% | |
| BDSI | Sell | BIODELIVERY SCIENCES INTL | $17,483,000 | +14.8% | 4,725,000 | -13.1% | 1.04% | +49.5% |
| PCRX | Sell | PACIRA PHARMACEUTICALS INC | $17,208,000 | -15.3% | 400,000 | -3.2% | 1.03% | +10.3% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $15,144,000 | -51.5% | 2,400,000 | +1.4% | 0.90% | -36.9% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $14,368,000 | +31.5% | 350,000 | +21.7% | 0.86% | +71.1% |
| PTCT | Sell | PTC THERAPEUTICS INC | $13,042,000 | -59.4% | 380,000 | -44.4% | 0.78% | -47.2% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC | $13,025,000 | +13.8% | 475,000 | 0.0% | 0.78% | +48.1% | |
| TLGT | Buy | TELIGENT INC | $7,261,000 | -65.3% | 5,300,000 | +0.0% | 0.43% | -54.8% |
| FENC | Buy | FENNEC PHARMACEUTICALS INC | $7,056,000 | -15.9% | 1,105,999 | +8.1% | 0.42% | +9.6% |
| KOD | New | KODIAK SCIENCES INC | $6,406,000 | – | 902,200 | +100.0% | 0.38% | – |
| YMAB | Y MABS THERAPEUTICS INC | $6,305,000 | -23.4% | 310,000 | 0.0% | 0.38% | -0.3% | |
| ALIM | Sell | ALIMERA SCIENCES INC | $4,481,000 | -26.7% | 6,240,000 | -0.0% | 0.27% | -4.6% |
| PTI | New | PROTEOSTASIS THERAPEUTICS INC | $4,212,000 | – | 1,300,000 | +100.0% | 0.25% | – |
| ACER | Sell | ACER THERAPEUTICS INC | $3,018,000 | -65.0% | 150,000 | -46.4% | 0.18% | -54.7% |
| PERNIX THERAPEUTICS HOLDINGS INCconvertible debt | $2,545,000 | -3.2% | 6,000,000 | 0.0% | 0.15% | +25.6% | ||
| XBI | New | SPDR SERIES TRUST - S&P BIOTECHcall | $1,440,000 | – | 500,000 | +100.0% | 0.09% | – |
| OTLK | New | OUTLOOK THERAPEUTICS INC | $340,000 | – | 680,000 | +100.0% | 0.02% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INCcall | $15,000 | – | 50,000 | +100.0% | 0.00% | – |
| ONSIW | Exit | ONCOBIOLOGICS INC - WARRANT Awarrant | $0 | – | -233,333 | -100.0% | 0.00% | – |
| QQQ | Exit | INVESCO QQQ TRUSTput | $0 | – | -500,000 | -100.0% | -0.01% | – |
| ONS | Exit | ONCOBIOLOGICS INC | $0 | – | -683,531 | -100.0% | -0.03% | – |
| ONCS | Exit | ONCOSEC MEDICAL INC | $0 | – | -500,000 | -100.0% | -0.03% | – |
| XBI | Exit | SPDR SERIES TRUST - S&P BIOTECHput | $0 | – | -1,500,000 | -100.0% | -0.05% | – |
| DBVT | Exit | DBV TECHNOLOGIES SAsponsored adr | $0 | – | -54,000 | -100.0% | -0.06% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.10% | – |
| PRNB | Exit | PRINCIPIA BIOPHARMA INC | $0 | – | -75,000 | -100.0% | -0.10% | – |
| TSRO | Exit | TESARO INC | $0 | – | -150,000 | -100.0% | -0.27% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AG | $0 | – | -147,368 | -100.0% | -0.30% | – |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -430,000 | -100.0% | -0.45% | – |
| SESN | Exit | SESEN BIO INC | $0 | – | -6,800,000 | -100.0% | -0.67% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS INC | $0 | – | -849,899 | -100.0% | -0.75% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -4,497,042 | -100.0% | -0.78% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -1,146,636 | -100.0% | -1.55% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -1,150,685 | -100.0% | -2.42% | – |
| ECYT | Exit | ENDOCYTE INC | $0 | – | -5,301,718 | -100.0% | -4.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.